N4 Pharma PLC New Nuvec(R) opportunity and patent filing (7167K)
24 April 2020 - 8:00AM
UK Regulatory
TIDMN4P
RNS Number : 7167K
N4 Pharma PLC
24 April 2020
24 April 2020
N4 Pharma Plc
("N4 Pharma" or the "Company")
New Nuvec(R) opportunity and patent filing
N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company
developing Nuvec(R), a novel delivery system for cancer treatments
and vaccines, announces that it has filed a new UK patent
application around both Nuvec(R)'s ability to be used to
manufacture viral vectors and to make viral vectors more efficient
in applications such as ex-vivo gene therapy treatments.
Nuvec(R) has a unique structure that allows the easy loading of
DNA plasmids. The manufacture of viral vectors typically requires
the use of two or more plasmids. Nuvec(R) has been shown to be
capable of loading multiple plasmids. In recent research conducted
by the Company, it has been demonstrated that loading Nuvec(R) with
the three plasmids typically used to produce lentivirus, resulted
in an increase in the amount of the desired viral vector produced.
The manufacture of viral vectors is an expensive process, so
utilising Nuvec(R)'s ability to efficiently load and deliver
multiple plasmids could greatly reduce the cost involved in this
process.
An important use of viral vectors is in ex-vivo gene therapy. In
this approach, a patient's cells are taken from their body and more
are grown in the laboratory. Whilst still outside the body, these
cells are modified by adding the gene of interest into the cells'
DNA by using viral vectors that are carrying the gene. These cells,
carrying the gene designed to treat the patient, are then
re-inserted back into the patient's body. In separate research, the
Company has demonstrated that when complexed with a lentivirus
carrying a gene of interest, Nuvec(R) can be used as a reagent to
produce cells containing the gene using a fraction of the original
lentivirus, thereby suggesting that this process can be made
cheaper and more efficient.
The Company is now working with external consultants to identify
how best to enter the virus manufacture and ex-vivo gene therapy
markets .
Nigel Theobald, Chief Executive Officer of the Company,
commented:
"Whilst investigating the dispersion of Nuvec(R) to improve its
in-vivo consistency, we have been undertaking research on the
in-vitro applications of Nuvec(R) as all our data shows good and
consistent loading and in-vitro transfection using Nuvec(R).
"The global viral vector manufacturing market was valued at $273
million in 2017 and is expected to grow to $816 million by 2023 .
Sales of transduction reagents were estimated to be $68m in 2017
and growing to $123m by 2024.
"These are significant markets for in-vitro applications of
Nuvec(R) and will allow us to look at additional commercial
opportunities whilst we continue to develop our in-vivo data
package for licensing Nuvec(R) as a delivery system for cancer
treatments and vaccines. "
Enquiries:
N4 Pharma Plc
Nigel Theobald, CEO Via Scott PR
Allenby Capital Limited Tel: +44(0)203 328 5656
James Reeve/Asha Chotai
Scott PR
Georgia Smith Tel: +44(0)1477 539 539
About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a
novel delivery system for vaccines and cancer treatments using its
unique silica nanoparticle delivery system called Nuvec(R).
N4 Pharma's business model is to partner with companies
developing novel antigens for vaccines and cancer treatments to use
Nuvec(R) as the delivery vehicle to get their antigen into cells to
express the protein needed for the required immunity. As these
products progress through pre clinical and clinical programs, N4
Pharma will seek to receive up front payments, milestone payments
and ultimately royalty payments once products reach the market.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCSESFMDESSEIL
(END) Dow Jones Newswires
April 24, 2020 02:00 ET (06:00 GMT)
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
N4 Pharma (LSE:N4P)
Historical Stock Chart
Von Jul 2023 bis Jul 2024